Novartis’s Gilenya MS Patient Share Growth in Europe Likely Driven by Improved Product Satisfaction and Efficacy-Related

  Novartis’s Gilenya MS Patient Share Growth in Europe Likely Driven by
  Improved Product Satisfaction and Efficacy-Related Performance Perceptions
  Among Neurologists, According to a Recent BioTrends Report

Business Wire

EXTON, Pa. -- December 05, 2012

BioTrends Research Group, one of the world’s leading research and advisory
firms for specialized biopharmaceutical issues, finds that Novartis’s Gilenya
captures 5.4 percent of those multiple sclerosis (MS) patients treated with
disease-modifying agents (DMAs) in the EU5 (France, Germany, Italy, Spain, and
the U.K.). This represents an increase from 2.3 percent share one year ago,
with significant growth seen among relapsing remitting MS (RRMS), primary
relapsing MS (PRMS) and secondary progressive MS (SPMS) patient segments.
Consistent with this growth in patient share, neurologists rate their overall
satisfaction with Gilenya and its performance on efficacy-related attributes,
such as relapse rate reduction, long-term, sustained efficacy and clinical
data support, significantly higher compared to 2011. However, it is important
to highlight that neurologists rate Biogen Idec/Élan’s Tysabri significantly
higher on overall satisfaction and performance than all other commercially
available DMAs, likely due to positive perceptions of Tysabri’s performance on
efficacy-related attributes.

TreatmentTrends: Multiple Sclerosis (EU) 2012 report also finds that the
greatest percent of neurologists continue to voice a first-line preference for
Biogen Idec’s Avonex or a high dose/high frequency interferon (Merck Serono’s
Rebif for RRMS and Bayer’s Betaferon for progressive MS). However, compared to
2011, significantly more neurologists report a preference for Gilenya as a
second-line therapy, drawing from Avonex and Teva’s Copaxone. Over the next
six months neurologists anticipate continuing to treat the greatest percent of
their MS patients with Avonex, although patient share for this DMA, along with
the other platform DMAs, are expected to contract significantly as Gilenya and
Tysabri patient shares grow.

Given the U.S. approval of Sanofi’s Aubagio one month prior to survey
fielding, it is interesting to note that significantly more EU5 neurologists
report aided awareness of Aubagio compared to 2011. However, even with the
recent approval activity, awareness of Aubagio continues to lag behind that of
Biogen Idec’s BG-12, Teva’s laquinimod, and Sanofi/Bayer’s alemtuzumab. BG-12,
in particular, stands out among the surveyed DMAs in development as the
product that neurologists are most interested in learning more about and as
the product that they perceive as potentially offering the greatest value to
the treatment of their MS patients, primarily due to expectations surrounding
its efficacy, oral administration and tolerability.

TreatmentTrends: Multiple Sclerosis (EU) is an annual syndicated report series
that provides a comprehensive view of the current and expected future
management of MS based on primary research across the European market (EU5).
The survey was fielded with 225 neurologists from France, Germany, Spain,
Italy, and the U.K. in October 2012. A parallel quarterly report covering the
U.S. is also available. These reports encompass the use of DMAs for the
treatment of MS, attitudes and perceptions toward these products, advantages
and disadvantages, ideal patient types, barriers to growth, and expected
future use. In addition, respondents are queried about their awareness of and
interest in DMAs in development.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or
www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.

Contact:

BioTrends Research Group
Emma Williams, 610-321-9441
ewilliams@bio-trends.com
or
Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com